Structure/Class |
- Endogenous catecholamine
|
Pharmacodynamics |
- Binds to α and β receptors (α1 = α2; β1 = β2 activity). Acts through G proteins leading to increase in cAMP and downstream effects.
- Organ system effects as follows:
- Cardiovascular
- Increased inotropy and chronotropy
- Vasoconstriction in almost all vascular beds (vasodilation in hepatic and skeletal muscle)
- Respiratory
|
Absorption/administration |
- IV (bolus/infusion). Can also be given IM/SC/Neb/ETT.
|
Distribution |
- Crosses the placenta, but does not cross BBB.
|
Metabolism |
- Metabolised at the sympathetic nerve ending via COMT/MAO pathways. Metabolised to VMA and excreted in the urine.
|
Excretion |
- Renal. T ½ of 1-3 minutes
|
Indications |
- Anaphylaxis and severe allergic reactions
- Cardiac arrest – facilitates increased blood flow secondary to vasoconstriction
- Asthma (nebulized)
- Croup
- Adjunct for LA – prolongs LA action and reduces bleeding.
|
Contraindications |
- IHD
- Severe hypertension
- Severe hyperthyroidism
- Phaeochromocytoma
- Glaucoma
|
Special precautions |
- Avoid using with LA in fingers/toes/ears
|
Interactions |
|
Adverse events |
- Increased cardiac irritability and arrhythmias
- Cerebral haemorrhage
- Increased BP
- Local ischemia
|
Dosing/administration |
- 300microg IM for anaphylactic reaction
- Bolus/infusion – start at 5mics/min and titrate as required.
|
Toxicology |
- If severe vasoconstriction (e.g. extravasation in digits) may be reversed with phentolamine (competitive antagonist at α1 and α2 receptors)
|
Withdrawal syndrome |
|
Special notes |
|